Business Context and Reporting Period
This Form 8-K was filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on March 28, 2022. The report serves to furnish the press release announcing financial results for the fiscal year ended December 31, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no specific financial metrics are available in this filing text.
Material Changes
The filing text does not disclose specific material changes or comparative data versus prior periods. It solely indicates that the full results for the year ended December 31, 2021, are contained in the attached press release.
Guidance, Outlook, and Risks
Management Commentary and Guidance: The text does not include management commentary, forward-looking guidance, or outlook statements. These are presumed to be in the referenced press release.
Risks and Contingencies: No specific risks or contingencies are detailed in this document. The filing includes a standard disclaimer that the furnished information is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name is ReShape Lifesciences Inc., as the input metadata incorrectly listed "Vyome Holdings, Inc."
- Review Exhibit 99.1 (the Press Release dated March 28, 2022) to obtain actual revenue, net income, and cash flow figures.
- Confirm the fiscal year end date of December 31, 2021 for accurate period comparison.
- Note that the financial data in this 8-K is "furnished" and not legally "filed" under Section 18 of the Exchange Act.